Clinical Trial Update: Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks [Phase 3]

View source ↗

Summary

Phase 3 safety study of two formulations of GSK's human rotavirus vaccine in healthy infants completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infections

Drugs mentioned

• HRV vaccine (Rotavirus vaccine) (human rotavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Rotavirus | Phase 3 | Status: COMPLETED | Results posted: 2021-06-18